Edwards Lifesciences Corporation $EW Stock Position Reduced by Patten & Patten Inc. TN

Patten & Patten Inc. TN cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 116,823 shares of the medical research company’s stock after selling 6,941 shares during the period. Patten & Patten Inc. TN’s holdings in Edwards Lifesciences were worth $9,959,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Strategic Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $35,000. Diversify Wealth Management LLC grew its position in Edwards Lifesciences by 1.2% during the fourth quarter. Diversify Wealth Management LLC now owns 46,816 shares of the medical research company’s stock valued at $3,925,000 after purchasing an additional 564 shares in the last quarter. Generali Asset Management SPA SGR grew its position in Edwards Lifesciences by 79.7% during the fourth quarter. Generali Asset Management SPA SGR now owns 72,539 shares of the medical research company’s stock valued at $6,184,000 after purchasing an additional 32,174 shares in the last quarter. MGO One Seven LLC grew its position in Edwards Lifesciences by 29.4% during the fourth quarter. MGO One Seven LLC now owns 24,515 shares of the medical research company’s stock valued at $2,090,000 after purchasing an additional 5,571 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in Edwards Lifesciences by 10.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 33,380 shares of the medical research company’s stock valued at $2,846,000 after purchasing an additional 3,143 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

EW stock opened at $79.86 on Friday. The company has a quick ratio of 3.09, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.98 billion, a price-to-earnings ratio of 42.48, a P/E/G ratio of 2.08 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The firm has a 50 day moving average of $82.16 and a two-hundred day moving average of $82.74.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EW. UBS Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. BTIG Research boosted their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $95.65.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. This represents a 51.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 88,096 shares of company stock valued at $7,288,799. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.